These findings suggest that DCs + lenalidomide + PD-1 blockade enhances therapeutic antitumor immunity by also inhibiting immunosuppressive cells in the tumor microenvironment during the vaccination phases. This evidence concerns the gene PDCD1 and neoplasm.